India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business